P2P Meth: Why Today's Supply Is Purer, More Abundant, and Possibly More Dangerous

After the US and Mexico restricted pseudoephedrine sales in 2006 and 2008, meth producers pivoted to a phenyl-2-propanone (P2P) synthesis route using widely available precursor chemicals. DEA seizure data shows P2P fully displaced ephedrine-based meth between 2009 and 2012, and synthesis methods have continued to shift — from ethyl phenylacetate routes, to nitrostyrene around 2014, back to phenylacetic acid around 2018. Early P2P meth contained roughly equal parts inactive l-meth and psychoactive d-meth, but by 2019 the product on the street was almost entirely d-meth, with overall purity near 95%.

The popular theory that lead acetate contamination explains a rise in meth-induced psychosis doesn’t fit the timeline: lead acetate is only used in the PAA route, which was largely abandoned during the 2014–2018 window when reports of severe behavioral effects were already climbing. What the data does support is a sheer volume story. Border seizures are skyrocketing, Seattle sewage biomarkers roughly doubled in 2017 and stayed elevated, and self-reported heavy daily use has tripled since 2015 even as casual use grew more modestly.

The upshot: whether or not P2P meth is pharmacologically distinct from the old ephedrine product, users today are consuming a purer, more potent drug in far greater quantities and more frequently — which alone could account for much of the observed harm without invoking a novel chemical mechanism.